ArriVent BioPharma (AVBP) Income Statement: Revenue & Earnings

ArriVent BioPharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

ArriVent BioPharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	79.00	64.88	30.43	8.58
Selling, General & Administrative	15.30	9.71	6.47	3.02
Operating Expenses	94.31	74.59	36.91	11.59
Operating Income	-94.31	-74.59	-36.91	-11.59
Other Income/Expense
Interest Income	13.82	5.26	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00
Other Income/Expense	13.82	0.00	0.00	0.00
Income
Income Before Tax	-80.49	-69.33	-36.91	-68.81
Income Tax Expense	0.00	0.00	0.00	0.00
Net Income	-80.49	-69.33	-36.91	-68.81
Net Income - Continuous Operations	-80.49	-69.33	-36.91	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-80.49	-74.59	-36.91	0.00
EBIT	-80.49	-74.59	-36.91	-11.59
Depreciation & Amortization	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-3.00	-32.00	-29.00	-97.00
Diluted EPS	-3.00	-32.00	-29.00	-97.00
Basic Shares Outstanding	31.47	2.14	1.28	0.71
Diluted Shares Outstanding	31.47	2.14	1.28	0.71